SI3237416T1 - Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba - Google Patents
Policiklične spojine karbamoilpiridona in njihova farmacevtska uporabaInfo
- Publication number
- SI3237416T1 SI3237416T1 SI201530743T SI201530743T SI3237416T1 SI 3237416 T1 SI3237416 T1 SI 3237416T1 SI 201530743 T SI201530743 T SI 201530743T SI 201530743 T SI201530743 T SI 201530743T SI 3237416 T1 SI3237416 T1 SI 3237416T1
- Authority
- SI
- Slovenia
- Prior art keywords
- polycyclic
- pharmaceutical use
- carbamoylpyridone compounds
- carbamoylpyridone
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096291P | 2014-12-23 | 2014-12-23 | |
EP15825729.5A EP3237416B1 (en) | 2014-12-23 | 2015-12-21 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
PCT/US2015/067155 WO2016106237A1 (en) | 2014-12-23 | 2015-12-21 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3237416T1 true SI3237416T1 (sl) | 2019-06-28 |
Family
ID=55168426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201530743T SI3237416T1 (sl) | 2014-12-23 | 2015-12-21 | Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba |
Country Status (24)
Country | Link |
---|---|
US (4) | US9522912B2 (sl) |
EP (2) | EP3237416B1 (sl) |
JP (3) | JP6393835B2 (sl) |
KR (4) | KR20210042185A (sl) |
CN (2) | CN111454273A (sl) |
AR (1) | AR103251A1 (sl) |
AU (3) | AU2015369817B2 (sl) |
BR (1) | BR102015032109A2 (sl) |
CA (1) | CA2969244C (sl) |
EA (1) | EA201791019A1 (sl) |
ES (1) | ES2732482T3 (sl) |
HK (1) | HK1244000B (sl) |
IL (1) | IL252532A0 (sl) |
MA (1) | MA45613A (sl) |
MX (1) | MX2017007814A (sl) |
NZ (1) | NZ732391A (sl) |
PL (1) | PL3237416T3 (sl) |
PT (1) | PT3237416T (sl) |
SG (1) | SG11201704421QA (sl) |
SI (1) | SI3237416T1 (sl) |
TR (1) | TR201909152T4 (sl) |
TW (2) | TWI695003B (sl) |
UY (1) | UY36465A (sl) |
WO (1) | WO2016106237A1 (sl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
AU2016244035B2 (en) * | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
BR112020008834A2 (pt) | 2017-11-02 | 2020-12-22 | Calico Life Sciences Llc | Moduladores da via de estresse integrada |
CA3080959A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US11091497B2 (en) * | 2017-12-08 | 2021-08-17 | The Rockefeller University | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation |
CR20230571A (es) * | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
WO2019230857A1 (ja) | 2018-05-31 | 2019-12-05 | 塩野義製薬株式会社 | 多環性ピリドン誘導体 |
EP4122537A1 (en) | 2019-03-22 | 2023-01-25 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
TW202120510A (zh) * | 2019-11-13 | 2021-06-01 | 大陸商上海拓界生物醫藥科技有限公司 | 新型四環雜環化合物及其藥物用途 |
JPWO2021107065A1 (sl) * | 2019-11-28 | 2021-06-03 | ||
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
US11697652B2 (en) | 2020-02-24 | 2023-07-11 | Gilead Sciences, Inc. | Tetracyclic compounds and uses thereof |
WO2022159387A1 (en) | 2021-01-19 | 2022-07-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
CN114736173B (zh) * | 2022-05-24 | 2024-06-11 | 无锡捷化医药科技有限公司 | 一种3-(二氟甲基)氧杂环丁烷-3-胺盐酸盐的制备方法 |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
DE69939749D1 (de) | 1998-12-25 | 2008-11-27 | Shionogi & Co | Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften |
AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
CN101513402B (zh) | 2001-08-10 | 2012-03-21 | 盐野义制药株式会社 | 抗病毒药 |
IL160642A0 (en) | 2001-10-03 | 2004-07-25 | Ucb Sa | Pyrrolidinone derivatives |
BRPI0213522C1 (pt) | 2001-10-26 | 2021-05-25 | St Di Ricerche Di Biologia Molecolare P Angeletti S P A | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto |
US7109186B2 (en) | 2002-07-09 | 2006-09-19 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
AU2003267098B2 (en) | 2002-09-11 | 2008-11-20 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors |
EP4059923A1 (en) | 2002-11-20 | 2022-09-21 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
WO2004049675A2 (en) * | 2002-11-26 | 2004-06-10 | Ambient Corporation | Arrangement of an inductive coupler for power line communications |
US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
CN101014574A (zh) | 2004-03-09 | 2007-08-08 | 默克公司 | Hiv整合酶抑制剂 |
WO2005110414A2 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
EP2229945A1 (en) | 2004-05-21 | 2010-09-22 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-HIV agents |
ES2720618T3 (es) | 2004-07-27 | 2019-07-23 | Gilead Sciences Inc | Análogos de fosfonato de compuestos de inhibidores de VIH |
EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
WO2006116764A1 (en) | 2005-04-28 | 2006-11-02 | Smithkline Beecham Corporation | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US20060249072A1 (en) * | 2005-05-05 | 2006-11-09 | Csillag Frank J | Method of synthesizing a fluoride growth material for improved outgassing |
EP1888581A2 (en) | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
CA2626956A1 (en) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
EP2308490A1 (en) | 2005-12-30 | 2011-04-13 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
JP2009525261A (ja) | 2006-02-01 | 2009-07-09 | 日本たばこ産業株式会社 | レトロウイルス感染症の治療のための、6−(3−クロロ−2−フルオロベンジル)−1−[(2s)−1−ヒドロキシ−3−メチルブタン−2−イル]−7−メトキシ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸またはその塩の使用 |
CN101437801B (zh) | 2006-03-06 | 2013-02-06 | 日本烟草产业株式会社 | 制备4-氧代喹啉化合物的方法 |
PL1992607T3 (pl) | 2006-03-06 | 2015-05-29 | Japan Tobacco Inc | Sposób wytwarzania związku 4-oksochinolinowego |
US7893055B2 (en) * | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
WO2008010953A2 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
MX2009002689A (es) | 2006-09-12 | 2009-03-26 | Gilead Sciences Inc | Proceso e intermediarios para preparar inhibidores de integrasa. |
EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
ES2603617T3 (es) | 2007-02-23 | 2017-02-28 | Gilead Sciences, Inc. | Moduladores de propiedades farmacocinéticas de la terapéutica |
US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
CN103480000A (zh) | 2007-06-29 | 2014-01-01 | 吉里德科学公司 | 治疗用组合物和方法 |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011816A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2320909B8 (en) * | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
PT2320908E (pt) | 2008-07-25 | 2014-03-06 | Shionogi & Co | Pró-fármacos de dolutegravir |
MX2011006241A (es) | 2008-12-11 | 2011-06-28 | Shionogi & Co | Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios. |
EP2367821B1 (en) * | 2008-12-17 | 2015-09-16 | Merck Patent GmbH | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
ES2688925T3 (es) | 2010-01-27 | 2018-11-07 | Viiv Healthcare Company | Tratamiento antiviral |
WO2011105590A1 (ja) | 2010-02-26 | 2011-09-01 | 日本たばこ産業株式会社 | 1,3,4,8-テトラヒドロ-2H-ピリド[1,2-a]ピラジン誘導体及びそのHIVインテグラーゼ阻害剤としての利用 |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
JP5806735B2 (ja) | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
CN106083891B (zh) | 2010-08-05 | 2018-03-23 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的化合物的制造方法 |
SI2620436T1 (sl) | 2010-09-24 | 2018-08-31 | Shionogi & Co., Ltd. | Predzdravilo substituiran policiklični karbamoilni piridonski derivat |
AP2015008931A0 (en) | 2011-04-21 | 2015-12-31 | Gilead Sciences Inc | Benzothiazole compounds and their pharmaceutical use |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
US9206197B2 (en) | 2011-09-14 | 2015-12-08 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
US9200009B2 (en) | 2011-10-12 | 2015-12-01 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase inhibitory activity |
WO2013091096A1 (en) | 2011-12-20 | 2013-06-27 | Boehringer Ingelheim International Gmbh | Condensed triclyclic compounds as inhibitors of hiv replication |
US9284323B2 (en) * | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
UY34750A (es) | 2012-04-20 | 2013-11-29 | Gilead Sciences Inc | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. |
WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
WO2014014933A1 (en) | 2012-07-20 | 2014-01-23 | Merck Sharp & Dohme Corp. | Hiv treatment with amido-substituted pyrimidinone derivatives |
EP2877469A4 (en) | 2012-07-25 | 2016-04-06 | Merck Sharp & Dohme | SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE |
US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
JP2016503030A (ja) | 2012-12-14 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 医薬組成物 |
WO2014099586A1 (en) | 2012-12-17 | 2014-06-26 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
KR102527797B1 (ko) * | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
EP2934482A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | ADMINISTRATIVE FORMULATIONS |
US20140221380A1 (en) | 2012-12-27 | 2014-08-07 | Japan Tobacco Inc. | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR |
US9493479B2 (en) * | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
EP3008044B1 (en) * | 2013-06-13 | 2018-11-21 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
EA030695B1 (ru) | 2013-09-27 | 2018-09-28 | Мерк Шарп И Доум Корп. | Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
AU2016244035B2 (en) * | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
-
2015
- 2015-12-10 TW TW104141539A patent/TWI695003B/zh active
- 2015-12-10 TW TW109115099A patent/TWI738321B/zh active
- 2015-12-21 US US14/977,347 patent/US9522912B2/en active Active
- 2015-12-21 BR BR102015032109A patent/BR102015032109A2/pt not_active Application Discontinuation
- 2015-12-21 EP EP15825729.5A patent/EP3237416B1/en active Active
- 2015-12-21 PL PL15825729T patent/PL3237416T3/pl unknown
- 2015-12-21 MA MA045613A patent/MA45613A/fr unknown
- 2015-12-21 WO PCT/US2015/067155 patent/WO2016106237A1/en active Application Filing
- 2015-12-21 SI SI201530743T patent/SI3237416T1/sl unknown
- 2015-12-21 PT PT15825729T patent/PT3237416T/pt unknown
- 2015-12-21 KR KR1020217010577A patent/KR20210042185A/ko not_active Application Discontinuation
- 2015-12-21 SG SG11201704421QA patent/SG11201704421QA/en unknown
- 2015-12-21 EP EP18173776.8A patent/EP3388431A1/en active Pending
- 2015-12-21 KR KR1020197013162A patent/KR102020004B1/ko active IP Right Grant
- 2015-12-21 CN CN202010421213.7A patent/CN111454273A/zh active Pending
- 2015-12-21 EA EA201791019A patent/EA201791019A1/ru unknown
- 2015-12-21 MX MX2017007814A patent/MX2017007814A/es unknown
- 2015-12-21 CA CA2969244A patent/CA2969244C/en active Active
- 2015-12-21 UY UY0001036465A patent/UY36465A/es not_active Application Discontinuation
- 2015-12-21 JP JP2017531320A patent/JP6393835B2/ja active Active
- 2015-12-21 AU AU2015369817A patent/AU2015369817B2/en active Active
- 2015-12-21 TR TR2019/09152T patent/TR201909152T4/tr unknown
- 2015-12-21 KR KR1020177020150A patent/KR101978167B1/ko active IP Right Grant
- 2015-12-21 ES ES15825729T patent/ES2732482T3/es active Active
- 2015-12-21 CN CN201580070876.6A patent/CN107108643B/zh active Active
- 2015-12-21 NZ NZ732391A patent/NZ732391A/en not_active IP Right Cessation
- 2015-12-21 KR KR1020197025726A patent/KR102240584B1/ko active IP Right Grant
- 2015-12-22 AR ARP150104261A patent/AR103251A1/es unknown
-
2016
- 2016-11-11 US US15/349,353 patent/US9795602B2/en active Active
-
2017
- 2017-05-25 IL IL252532A patent/IL252532A0/en unknown
- 2017-09-14 US US15/704,842 patent/US10646486B2/en active Active
-
2018
- 2018-03-12 HK HK18103442.8A patent/HK1244000B/zh unknown
- 2018-07-20 JP JP2018136915A patent/JP6934846B2/ja active Active
-
2019
- 2019-01-22 AU AU2019200422A patent/AU2019200422B2/en active Active
-
2020
- 2020-01-07 JP JP2020000897A patent/JP2020073560A/ja active Pending
- 2020-03-27 US US16/832,230 patent/US20210015816A1/en not_active Abandoned
- 2020-12-10 AU AU2020286299A patent/AU2020286299B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244000B (zh) | 多環氨基甲酰吡啶酮化合物及其藥物用途 | |
HK1249103B (zh) | 多環氨甲醯基吡啶酮化合物及其藥物用途 | |
HK1243073A1 (zh) | 治療性化合物及其用途 | |
GB201403093D0 (en) | Therapeutic compounds and their use | |
IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
HK1232211A1 (zh) | 二甲基吡啶胺衍生物及其醫藥用途 | |
ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
GB201702464D0 (en) | Pharmaceutical agent | |
GB201406115D0 (en) | New pharmaceutical use | |
GB201517133D0 (en) | New pharmaceutical use | |
GB201409662D0 (en) | New pharmaceutical use | |
GB201616767D0 (en) | New pharmaceutical use | |
GB201517454D0 (en) | New pharmaceutical use | |
GB201517132D0 (en) | New pharmaceutical use | |
GB201508613D0 (en) | New pharmaceutical use | |
GB201508611D0 (en) | New pharmaceutical use | |
GB201507813D0 (en) | New pharmaceutical use | |
GB201410387D0 (en) | Compounds and their therapeutic use | |
GB201403496D0 (en) | Compounds and their therapeutic use | |
GB201413411D0 (en) | Novel compounds and their use |